


The background of the slide is a close-up, high-resolution image of water ripples. The water is a deep blue color, and the ripples create a complex pattern of light and dark blue lines and curves, giving it a textured, almost abstract appearance. The lighting seems to come from above, creating highlights on the peaks of the ripples and shadows in the valleys.

TCRA is a *Special Situation*

TCRA is a *Special Situation*

TCRA's philanthropic endowments will save the lives of **2 million** babies dying annually in The Global South. This deck describes the TCRA business plan that can raise **\$70 billion** for WIRhE and GAVI in the very short term.

TCRA is a *Special Situation*

The big four clinical lab automation manufacturers, *Siemens, Abbott, Roche, and Beckman Coulter* (BIG4) are a huge powerful oligopoly with a lock on the world clinical lab automation market.

TCRA is a *Special Situation*

The BIG4 are experts in developing, making, and selling advanced clinical lab automation systems worldwide. The BIG4 have client labs all over the world. They know the market. Wall Street will accept projections made by these four major companies at their word.

TCRA is a *Special Situation*

TCRA has a portfolio of International and US patents on Dark Lab Automation, DLA. In the hands of the BIG 4, these patents can generate **\$1 trillion** in royalties for TCRA shareholders over 20 years.

TCRA is a *Special Situation*

The huge BIG4 companies will announce with great confidence that they will switch the world's clinical labs to TCRA-patented DLA and generate **\$1 trillion** in royalties for TCRA shareholders.

TCRA is a *Special Situation*

TCRA, owner of the DLA patents, is a very special situation. TCRA company value will greatly increase in one day, the day the BIG4, *Siemens, Abbott, Roche, and Beckman Coulter*, announce they will use best efforts to make DLA the standard automation in the worlds' labs.

TCRA is a *Special Situation*

TCRA company value will rise to **\$300 billion** when the big four manufacturers announce they have licensed DLA and intend to make DLA the world's standard clinical lab automation system. Their decision to announce will provide the funds to save **2 million** babies lives annually.

TCRA is a *Special Situation*

The price investors will pay for TCRA shares after the BIG4 announcement is best estimated with a discounted cash flow model for expected DLA royalties over **20 years** using an appropriate risk adjusted discount rate. This model generates a PV of **\$300 billion** for the patent portfolio.

TCRA is a *Special Situation*

The BIG4 all announce DLA programs

WHAM! BANG! KABOOM!

TCRA shares will skyrocket.

TCRA is a *Special Situation*

In today's clinical labs that use TLA, only movement of samples is automated. All of the other items, reagents, test tubes, pipet tips, fluids and other supplies required for a clinical lab test have to be moved from the lab supply storeroom and manually installed in multiple analyzers throughout the lab.

TCRA is a *Special Situation*

In a future DLA clinical lab all of the items required for a test are stored on the integrated DLA analyzer itself. They are transported automatically to analytic modules on the analyzer that will perform the tests. No humans in a lab run with the lights out.

TCRA is a *Special Situation*

Each of the BIG4's **8%** of TCRA will become worth **\$80 billion** in royalties. Their stocks will double. Their DLA programs will be fully funded upfront by sales of TCRA stock. DLA will protect Big 4's clinical lab automation market shares because TLA cannot compete with DLA. The TCRA deal is so good that BIG4 must sign on.

TCRA is a *Special Situation*

The capital structure of TCRA before the announcements will be Rockefeller Foundation 50%, BIG4 32%, PE firm 8%, Early investors 10%.

TCRA is a *Special Situation*

The numbers that underpin DLA are so compelling that they do not need to be highlighted. BIG4's revenue opportunity will make their DLA announcements a straightforward business decision, once they understand the deal. The TCRA deal is a slam dunk for the BIG4.

TCRA is a *Special Situation*

Rockefeller sells TCRA shares at the new high price to raise \$10 billion for WIRhE, \$60 billion for GAVI/UNICEF

TCRA is a Special Situation

How do we get access to BIG4 corporate development to explain their huge opportunity?
We have no access to BIG4 executives. Here is our access plan.

TCRA is a *Special Situation*

We will approach a top venture firm, have them arrange for influential billionaires to invest in TCRA. These finance titans, our '*Rh Club*', will meet with executives and board members of BIG4 to present them with BIG4's enormous financial, business, and world health opportunity.

TCRA is a *Special Situation*

Early investors will be allowed to acquire **2%** of TCRA stock once they commit to use every resource to make the BIG4 see their huge opportunity. **2%** will mean **\$16 billion** in future royalties when they persuade Big 4 to act. Their action will save an Rh baby every **4 minutes**.

TCRA is a *Special Situation*

Once the BIG4 has made the announcement and the TCRA price has risen, Big 4, PE firm, Early investors including the Rh Club members, will sell shares on a secondary market. The Rockefeller Foundation will use some of their **\$500 billion** royalties to endow WIRhE and GAVI/UNICEF in perpetuity.

TCRA is a *Special Situation*

How long will it take to get the '*Rh Club*' on board and for them to get all BIG4 to announce their DLA program? In many discussions, no one could provide any reasons why it would take more than two months, making it the fastest deal of this size in Wall Street history.

TCRA is a *Special Situation*

Lack of funds for proven preventive programs are resulting in **2 million** babies dying needlessly every year in the Global South. This deck outlines a straightforward high finance way to provide more than adequate funds in the very short term to save those babies.

High finance with a heart